Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK
Authors
Earl, H. M.Hiller, L.
Dunn, J.
Macpherson, I.
Rea, D.
Hughes-Davies, L.
McAdam, K.
Hall, P.
Mansi, J.
Wheatley, D.
Abraham, J. E.
Caldas, C.
Gasson, S.
O'Riordan, E.
Wilcox, M.
Miles, D.
Cameron, D. A.
Wardley, Andrew M
Affiliation
Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK;Issue Date
2020
Metadata
Show full item recordCitation
Earl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, et al. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clinical Oncology. 2020.Journal
Clinical OncologyDOI
10.1016/j.clon.2020.07.006PubMed ID
32723485Additional Links
https://dx.doi.org/10.1016/j.clon.2020.07.006Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2020.07.006